Bumbacea R, Udrea M, Ali S, Bojinca V
Int J Mol Sci. 2024; 25(9).
PMID: 38732026
PMC: 11084733.
DOI: 10.3390/ijms25094807.
Doig C, Cooke R, Chua C, Leung T
BMJ Case Rep. 2022; 15(2).
PMID: 35115328
PMC: 8814741.
DOI: 10.1136/bcr-2021-242316.
Kuroshima S, Nakajima K, Sasaki M, I T, Sumita Y, Asahara T
Stem Cell Res Ther. 2019; 10(1):209.
PMID: 31311585
PMC: 6636115.
DOI: 10.1186/s13287-019-1308-8.
Skeoch S, Weatherley N, Swift A, Oldroyd A, Johns C, Hayton C
J Clin Med. 2018; 7(10).
PMID: 30326612
PMC: 6209877.
DOI: 10.3390/jcm7100356.
Kouroukis C, Chia S, Verma S, Robson D, Desbiens C, Cripps C
Curr Oncol. 2008; 15(1):9-23.
PMID: 18317581
PMC: 2259432.
DOI: 10.3747/co.2008.198.
Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
Yokose N, Ogata K, Tamura H, An E, Nakamura K, Kamikubo K
Br J Cancer. 1998; 77(12):2286-90.
PMID: 9649147
PMC: 2150381.
DOI: 10.1038/bjc.1998.380.
Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96.
Niitsu N, Iki S, Muroi K, Motomura S, Murakami M, Takeyama H
Br J Cancer. 1997; 76(12):1661-6.
PMID: 9413959
PMC: 2228212.
DOI: 10.1038/bjc.1997.614.
Clinical toxicity of cytokines used as haemopoietic growth factors.
Vial T, Descotes J
Drug Saf. 1995; 13(6):371-406.
PMID: 8652081
DOI: 10.2165/00002018-199513060-00006.
Growth factors and hematopoietic recovery.
Gulati S, Gopal R, Prowda J, Spanik S, Jain M, Gopal A
Med Oncol. 1994; 11(1):1-6.
PMID: 7921922
DOI: 10.1007/BF02990084.
Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.
Lei K, Leung W, Johnson P
Br J Cancer. 1994; 70(5):1009-13.
PMID: 7524599
PMC: 2033539.
DOI: 10.1038/bjc.1994.439.
Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.
Schwab G, Hecht T
Ann Hematol. 1994; 69(1):1-9.
PMID: 7520285
DOI: 10.1007/BF01757341.